Table 1 |
|||||
|
Fetal loss and cardiac abnormality in NaVP exposed dams |
|||||
|
Treatment (Gestation) |
No. of dams |
Total No. of Live fetuses (fetus/dam) |
N. of death or resorption |
Cardiac abnormalities |
|
|
|
|||||
|
No. in live fetus |
% |
||||
|
|
|||||
|
Day 6 |
|||||
|
Control |
10 |
163 (16.3) |
2 |
1 |
0.60 |
|
Treated |
20 |
148 (7.4)* |
63* |
13 |
8.70* |
|
Day 7 |
|||||
|
Control |
12 |
148 (12.3) |
3 |
1 |
0.67 |
|
Treated |
24 |
162 (6.75)* |
90* |
34 |
20.90* |
|
Day 8 |
|||||
|
Control |
10 |
147 (14.7) |
3 |
0 |
0.00 |
|
Treated |
20 |
132 (6.6)* |
78* |
13 |
9.80* |
|
Day 9 |
|||||
|
Control |
10 |
149 (14.9) |
1 |
1 |
0.68 |
|
Treated |
20 |
142 (7.1)* |
60* |
9 |
6.30* |
|
|
|||||
|
Pregnant female mice received a one-time injection (i.p.) of NaVP (700 mg/kg body weight) on gestation day as indicated. The fetuses were examined on gestation day 19 after sacrifice of the pregnant mice as described in Materials and Methods. * P < 0.05 compared to controls. |
|||||
|
Wu et al. Journal of Biomedical Science 2010 17:16 doi:10.1186/1423-0127-17-16 |
|||||